FLT3 and acute myeloid leukemia: The study evaluated 371 patients in first CR who received HSCT and showed that the presence of FLT3 internal tandem duplication (FLT3/ITD) and NPM1 variants before HSCT were associated with increase rates of relapse and poor survival, results that also underscore the need for NGS-MRD assessment to obtain best outcomes in AML patients [33].